Product Name: Trastuzumab
Synonyms: Herceptin;TrastuzuMab(Herceptin);TRASTUZUMAB 98 % +;IMMunoglobulin G1,anti-(huMan p185neu receptor) (huMan-Mouse Monoclonal rhuMab HER2 g1-chain), disulfide with huMan-MouseMonoclonal rhuMab HER2 light chain, diMer;TRASTUZUMAB 95 % +;Anti HER2, Ig gamma-1 chain C region;Trastuzumab - 20mg/ml in PBS;Recombinant humanized anti-HER2 antibody
CAS: 180288-69-1
MF: C10H14N6O5
MW: 298.25536
EINECS:
Product Categories: -
Mol File: 180288-69-1.mol
Trastuzumab Structure
Trastuzumab Chemical Properties
Safety Information
MSDS Information
Trastuzumab Usage And Synthesis
Indications The introduction of herceptin (Trastuzumab) into clinical practice for the treatment of breast cancer marks a major advance in the use of monoclonal antibody cancer therapy. Herceptin is a humanized antibody directed against the HER-2 antigen that is overexpressed on the tumor cell surface in approximately 25% of breast cancer patients. HER-2/neu/erbB2 overexpression marks an aggressive estrogen receptor–negative form of breast cancer. Therefore, a therapeutic agent selective for this target is particularly valuable. Herceptin is administered by intravenous infusion and in conjunction with paclitaxel can extend survival in patients with HER-2/neu/erbB2 overexpressing metastatic breast cancer.Herceptin use is associated with infusion- related hypotension, flushing and bronchoconstriction, and skin rash but no bone marrow toxicity. Herceptin appears to sensitize patients to cardiotoxicity, an important concern in patients also receiving doxorubicin.
China
